[1] Filizoglu N, Ozguven S. Neurofibromatosis type 2:multiple meningiomatosis and vestibular schwannomas on 68 Ga-DOTATATE PET/CT[J]. Clin Nucl Med, 2022, 47:e710-712. [2] Ren Y, Chari DA, Vasilijic S, Welling DB, Stankovic KM. New developments in neurofibromatosis type 2 and vestibular schwannoma[J]. Neurooncol Adv, 2020, 3:vdaa153. [3] Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis[J]. Int J Mol Sci, 2021, 22:5850. [4] Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN, Zuccarello M, Schorry E, Sengupta S. Neurofibromatosis type 2(NF2) and the implications for vestibular schwannoma and meningioma pathogenesis[J]. Int J Mol Sci, 2021, 22:690. [5] Wang VY, Liu TY, Fang TY, Chen YH, Huang CJ, Wang PC. Clinical manifestations and genetic analysis of a family with neurofibromatosis type 2[J]. Acta Otolaryngol, 2022, 142:36-42. [6] Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. An update on the CNS manifestations of neurofibromatosis type 2[J]. Acta Neuropathol, 2020, 139:643-665. [7] Gugel I, Grimm F, Teuber C, Kluwe L, Mautner VF, Tatagiba M, Schuhmann MU. Management of NF2-associated vestibular schwannomas in children and young adults:influence of surgery and clinical factors on tumor volume and growth rate[J]. J Neurosurg Pediatr, 2019.[Epub ahead of print] [8] Rajendran S, Antonios J, Solomon B, Kim HJ, Wu T, Smirniotopoulos J, Scott G, Benzo S, Hayes C, Heiss JD, Chittiboina P. A prospective evaluation of swallowing and speech in patients with neurofibromatosis type 2[J]. J Neurol Surg B Skull Base, 2021, 82:244-250. [9] Helbing DL, Schulz A, Morrison H. Pathomechanisms in schwannoma development and progression[J]. Oncogene, 2020, 39:5421-5429. [10] Yao L, Alahmari M, Temel Y, Hovinga K. Therapy of sporadic and NF2-related vestibular schwannoma[J]. Cancers (Basel), 2020, 12:835. [11] Li SW, Zhang J, Tang HL, Li P, Wang B, Zhao F, Liu PN. Establishment of nomograms for the prediction of useful hearing loss in patients with neurofibromatosis type 2[J]. J Neurooncol, 2021, 155:373-381. [12] Gugel I, Zipfel J, Hartjen P, Kluwe L, Tatagiba M, Mautner VF, Schuhmann MU. Managing NF2-associated vestibular schwannomas in children and young adults:review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality[J]. Childs Nerv Syst, 2020, 36:2471-2480. [13] Lerner DK, Lee D, Naples JG, Brant JA, Bigelow D, Alonso-Basanta M, Ruckenstein MJ. Factors associated with facial nerve paresis following Gamma Knife for vestibular schwannoma[J]. Otol Neurotol, 2020, 41:e83-88. [14] Jia H, Nguyen Y, Hochet B, Smail M, Mosnier I, Wu H, Sterkers O, Kalamarides M, Bernardeschi D. NF2-related intravestibular schwannomas:long-term outcomes of cochlear implantation[J]. Otol Neurotol, 2020, 41:94-99. [15] Morselli C, Boari N, Artico M, Bailo M, Piccioni LO, Giallini I, de Vincentiis M, Mortini P, Mancini P. The emerging role of hearing loss rehabilitation in patients with vestibular schwannoma treated with Gamma Knife radiosurgery:literature review[J]. Neurosurg Rev, 2021, 44:223-238. [16] Kim J, Byeon Y, Song SW, Cho YH, Hong CK, Hong SH, Kim JH, Lee DH, Park JE, Kim HS, Kim YH. Vestibular schwannoma associated with neurofibromatosis type 2:clinical course following stereotactic radiosurgery[J]. Front Oncol, 2022, 12:996186. [17] Tosi U, Maayan O, An A, Lavieri MET, Guadix SW, DeRosa AP, Christos PJ, Pannullo S, Stieg PE, Brandmaier A, Knisely JPS, Ramakrishna R. Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients:a systematic review and meta-analysis[J]. J Neurooncol, 2022, 156:431-441. [18] Whitmeyer M, Brahimaj BC, Beer-Furlan A, Alvi S, Epsten MJ, Crawford F, Byrne RW, Wiet RM. Resection of vestibular schwannomas after stereotactic radiosurgery:a systematic review[J]. J Neurosurg, 2020.[Epub ahead of print] [19] Chung LK, Nguyen TP, Sheppard JP, Lagman C, Tenn S, Lee P, Kaprealian T, Chin R, Gopen Q, Yang I. A systematic review of radiosurgery versus surgery for neurofibromatosis type 2 vestibular schwannomas[J]. World Neurosurg, 2018, 109:47-58. [20] Kruyt IJ, Verheul JB, Hanssens PEJ, Kunst HPM. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis type 2:a matched cohort study with sporadic vestibular schwannomas[J]. J Neurosurg, 2018, 128:49-59. [21] Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2[J]. N Engl J Med, 2009, 361:358-367. [22] Lu VM, Ravindran K, Graffeo CS, Perry A, Van Gompel JJ, Daniels DJ, Link MJ. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2:a systematic review and meta-analysis of treatment outcomes[J]. J Neurooncol, 2019, 144:239-248. [23] Goutagny S, Kalamarides M. Medical treatment in neurofibromatosis type 2:review of the literature and presentation of clinical reports[J]. Neurochirurgie, 2018, 64:370-374. [24] Sanchez LD, Bui A, Klesse LJ. Targeted therapies for the neurofibromatoses[J]. Cancers (Basel), 2021, 13:6032. [25] Eitutis ST, Jansen T, Borsetto D, Scoffings DJ, Tam YC, Panova T, Tysome JR, Donnelly NP, Axon PR, Bance ML. Cochlear Implantation in NF2 patients without intracochlear schwannoma removal[J]. Otol Neurotol, 2021, 42:1014-1021. [26] Tadokoro K, Bartindale MR, El-Kouri N, Moore D, Britt C, Kircher M. Cochlear implantation in vestibular schwannoma:a systematic literature review[J]. J Neurol Surg B Skull Base, 2021, 82:643-651. [27] Tian L, West N, Cayé-Thomasen P. Cochlear implantation after radiotherapy of vestibular schwannomas[J]. J Int Adv Otol, 2021, 17:452-460. [28] Patel NS, Carlson ML, Link MJ, Neff BA, Van Gompel JJ, Driscoll CLW. Cochlear implantation after radiosurgery for vestibular schwannoma[J]. J Neurosurg, 2021, 135:126-135. [29] Deep NL, Patel EJ, Shapiro WH, Waltzman SB, Jethanamest D, McMenomey SO, Roland JT Jr, Friedmann DR. Cochlear implant outcomes in neurofibromatosis type 2:implications for management[J]. Otol Neurotol, 2021, 42:540-548. [30] Wick CC, Butler MJ, Yeager LH, Kallogjeri D, Durakovic N, McJunkin JL, Shew MA, Herzog JA, Buchman CA. Cochlear implant outcomes following vestibular schwannoma resection:systematic review[J]. Otol Neurotol, 2020, 41:1190-1197. [31] Egra-Dagan D, van Beurden I, Barber SR, Carter CL, Cunnane ME, Brown MC, Herrmann BS, Lee DJ. Adult auditory brainstem implant outcomes and three-dimensional electrode array position on computed tomography[J]. Ear Hear, 2021, 42:1741-1754. [32] Wang DX, Wang S, Jian MY, Han RQ. Awake craniotomy for auditory brainstem implant in patients with neurofibromatosis type 2:four case reports[J]. World J Clin Cases, 2021, 9:7512-7519. [33] Dhanasingh A, Hochmair I. ABI-auditory brainstem implant[J]. Acta Otolaryngol, 2021, 141:63-81. [34] Sanna M, Di Lella F, Guida M, Merkus P. Auditory brainstem implants in NF2 patients:results and review of the literature[J]. Otol Neurotol, 2012, 33:154-164. [35] Maini S, Cohen MA, Hollow R, Briggs R. Update on long-term results with auditory brainstem implants in NF2 patients[J]. Cochlear Implants Int, 2009, 10 Suppl 1:33-37. [36] Noonan KY, Rock J, Barnard Z, Lekovic GP, Brackmann DE, Wilkinson EP. Bilateral auditory brainstem implants in patients with neurofibromatosis 2[J]. Otolaryngol Head Neck Surg, 2021, 165:339-343. |